---
title: "SLU-PP-332"
canonical_url: https://peptidelibrary.app/library/slu-pp-332
description: "Pan-estrogen-related-receptor agonist studied as an exercise mimetic in mice (2023). Not a peptide and not FDA-approved."
updated: 2026-09-06
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# SLU-PP-332

SLU-PP-332 (also called ERR agonist or Exercise-mimetic small molecule) is an ERR agonist. SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors ERRalpha, ERRbeta and ERRgamma, orphan nuclear receptors that act as transcriptional regulators of oxidative metabolism.

Pan-estrogen-related-receptor agonist studied as an exercise mimetic in mice (2023). Not a peptide and not FDA-approved.

Also known as: ERR agonist, Exercise-mimetic small molecule.

Categories: Fat Loss, Muscle/Recovery, GLP-1/Metabolic, Experimental.

## Classification

- Type: ERR agonist / small molecule research
- Mechanism class: ERR Agonist
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors ERRalpha, ERRbeta and ERRgamma, orphan nuclear receptors that act as transcriptional regulators of oxidative metabolism. Activating them increases expression of genes governing mitochondrial biogenesis, fatty-acid oxidation and oxidative phosphorylation, producing in rodents a transcriptional pattern resembling the adaptation to endurance exercise, together with increased energy expenditure. It is a small molecule rather than a peptide and is not approved for any use; the published work is preclinical, with no human pharmacokinetic or safety data.

Targets: ERRα, ERRβ, ERRγ.

Origin: Synthetic small-molecule ERR agonist.

## Properties

- Molecular formula: C18H14N2O2
- Molecular weight: 467.5 g/mol
- CAS number: 303760-60-3
- Half-life: Not established

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Lab & animal studies
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 3
- Latest source: 2024

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Synthetic ERR alpha/beta/gamma Agonist Induces an ERR alpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023. 2023. Preclinical: animal or lab study. Population: Three-month-old male C57BL/6J mice, 8-10 per group. Increased type IIa oxidative fibres, enhanced treadmill endurance, and induction of an ERR-alpha-dependent acute aerobic exercise gene programme. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/36988910/)
2. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024. 2024. Preclinical: animal or lab study. Population: Diet-induced obese and ob/ob mice. Increased energy expenditure and fatty acid oxidation, decreased fat mass, improved insulin sensitivity. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/37739806/)
3. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024. 2024. Preclinical: animal or lab study. Population: Rodent heart failure model. Improved cardiac fatty acid metabolism and mitochondrial function. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/37961903/)

## Safety

Side effects: No established human safety.

Risks: Research-only small molecule.

Contraindications: Hormone-sensitive cancers.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

SLU-PP-332 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is SLU-PP-332?

Pan-estrogen-related-receptor agonist studied as an exercise mimetic in mice (2023). Not a peptide and not FDA-approved.

### How does SLU-PP-332 work?

SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors ERRalpha, ERRbeta and ERRgamma, orphan nuclear receptors that act as transcriptional regulators of oxidative metabolism. Activating them increases expression of genes governing mitochondrial biogenesis, fatty-acid oxidation and oxidative phosphorylation, producing in rodents a transcriptional pattern resembling the adaptation to endurance exercise, together with increased energy expenditure.

### Is SLU-PP-332 FDA approved?

No. SLU-PP-332 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What peptides are similar to SLU-PP-332?

Compounds most often compared with SLU-PP-332 include 5-Amino-1MQ, BAM15, AICAR and Tesofensine. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [\[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications\] — Rev Med Chil, 2026](https://pubmed.ncbi.nlm.nih.gov/42024694/)
- [Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling — Int J Biol Macromol, 2026](https://pubmed.ncbi.nlm.nih.gov/41850449/)
- [Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes — Drug Test Anal, 2026](https://pubmed.ncbi.nlm.nih.gov/41688415/)
- [In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential — Rapid Commun Mass Spectrom, 2026](https://pubmed.ncbi.nlm.nih.gov/41588687/)
- [A Synthetic ERR Agonist Alleviates Metabolic Syndrome — J Pharmacol Exp Ther, 2024](https://pubmed.ncbi.nlm.nih.gov/37739806/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
